Content deleted Content added
Citation bot (talk | contribs) Add: date. | Use this bot. Report bugs. | Suggested by Abductive | Category:Chemicals using indexlabels | #UCB_Category 333/675 |
m →Research: clean up, replaced: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research → Medical Science Monitor |
||
Line 153:
{{as of|March 2016}}, there were other phase III trials registered for thyroid cancer,<ref>{{cite journal | title=Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer (ASTRA) | website=ClinicalTrials.gov | date=30 April 2013 | url=https://clinicaltrials.gov/ct2/show/NCT01843062 | access-date=10 April 2020 | archive-date=11 April 2020 | archive-url=https://web.archive.org/web/20200411011921/https://clinicaltrials.gov/ct2/show/NCT01843062 | url-status=live }}</ref> and ''[[KRAS]]'' positive NSCLC.<ref>{{cite web | title=Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1) | website=ClinicalTrials.gov | date=2 September 2013 | url=https://clinicaltrials.gov/ct2/show/NCT01933932 | access-date=10 April 2020 | archive-date=11 April 2020 | archive-url=https://web.archive.org/web/20200411011928/https://clinicaltrials.gov/ct2/show/NCT01933932 | url-status=live }}</ref> The combination of selumetinib to chemotherapy improved median progression-free survival in a trial of 510 patients with advanced ''KRAS''-mutant NSCLC just for one month, which was statistically not significant.<ref name="pmid28492898">{{cite journal | vauthors=Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J | display-authors = 6 | title = Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial | journal = JAMA | volume = 317 | issue = 18 | pages = 1844–53 | date = May 2017 | pmid = 28492898 | pmc = 5815037 | doi = 10.1001/jama.2017.3438 }}</ref>
In November 2018, investigators working with [[Nasal polyp|nasal polyp tissue]] ''in vitro'' demonstrated a synergistic effect of down regulating expression of p-MEK1 and p-[[ERK1]] when it was administered with [[erythromycin]].<ref>{{cite journal|pmid=30414267|date = November 2018| vauthors = Liu X, Wang X, Chen L, Shi Y, Wei Y |title=Effects of Erythromycin on the Proliferation and Apoptosis of Cultured Nasal Polyp-Derived Cells and the Extracellular Signal-Regulated Kinase (ERK)/Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway|journal=Medical Science Monitor
== References ==
| |||